Holen Sie sich die Stockscreener-App
8.47
1.93%
0.16
Handel nachbörslich:
8.50
0.03
+0.35%
Schlusskurs vom Vortag:
$8.31
Offen:
$8.32
24-Stunden-Volumen:
311.78K
Relative Volume:
0.94
Marktkapitalisierung:
$478.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-3.50
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
+10.14%
1M Leistung:
+14.00%
6M Leistung:
+109.65%
1J Leistung:
-27.11%
1-Tages-Spanne:
$8.08
$8.5925
1-Wochen-Bereich:
$7.3566
$8.69
52-Wochen-Spanne:
$3.555
$12.52
Astria Therapeutics Inc Stock (ATXS) Company Profile
Firmenname
Astria Therapeutics Inc
Sektor
Branche
Telefon
617-349-1971
Adresse
22 BOSTON WHARF ROAD, BOSTON
Vergleichen Sie ATXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
8.47 | 468.97M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | TD Cowen | Buy |
| 2023-03-28 | Eingeleitet | Evercore ISI | Outperform |
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
What to do if you’re stuck in Astria Therapeutics Inc.Portfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com
Is it too late to sell Astria Therapeutics Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed - MSN
Can Astria Therapeutics Inc. stock sustain institutional interest2025 Market Outlook & High Conviction Buy Zone Alerts - newser.com
Comparing Astria Therapeutics Inc. in custom built stock radars2025 Retail Activity & Verified Entry Point Signals - newser.com
How to forecast Astria Therapeutics Inc. trends using time seriesWeekly Gains Report & Consistent Profit Alerts - newser.com
Visual analytics tools that track Astria Therapeutics Inc. performanceJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Tick level data insight on Astria Therapeutics Inc. volatility2025 Winners & Losers & Technical Entry and Exit Tips - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
H.C. Wainwright reiterates Buy rating on Astria Therapeutics stock at $20 - Investing.com Canada
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting - Business Wire
Analyzing Astria Therapeutics Inc. with multi timeframe chartsEarnings Risk Summary & Reliable Price Breakout Signals - newser.com
How to interpret RSI for Astria Therapeutics Inc. stock2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Astria Therapeutics begins phase 3 long-term trial for HAE treatment - Investing.com Nigeria
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with - PharmiWeb.com
Astria Therapeutics (ATXS) Begins Phase 3 Trial for Hereditary A - GuruFocus
Astria Therapeutics initiates the phase 3 ORBIT-EXPANSE long-term trial of navenibart in people with hereditary angioedema - MarketScreener
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema - Business Wire
Astria Therapeutics, Inc. $ATXS Stock Position Lifted by Farther Finance Advisors LLC - Defense World
How strong is Astria Therapeutics Inc. stock balance sheetJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Predicting Astria Therapeutics Inc. trend using moving averages2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
What’s the recovery path for long term holders of Astria Therapeutics Inc.Quarterly Trade Report & Fast Moving Stock Watchlists - newser.com
Using Ichimoku Cloud for Astria Therapeutics Inc. technicalsWeekly Gains Summary & Free Technical Pattern Based Buy Signals - newser.com
Will Astria Therapeutics Inc. outperform the marketRate Cut & Free Fast Gain Swing Trade Alerts - newser.com
Will breakout in Astria Therapeutics Inc. lead to full recovery2025 Analyst Calls & Capital Protection Trading Alerts - newser.com
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA - Business Wire
Will Astria Therapeutics Inc. bounce back from current supportPortfolio Return Report & Free Technical Confirmation Trade Alerts - newser.com
Momentum divergence signals in Astria Therapeutics Inc. chartStop Loss & Growth Focused Investment Plans - newser.com
Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial - BioSpace
Astria Therapeutics expands phase 3 HAE trial to European Union By Investing.com - Investing.com Nigeria
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Astria Therapeutics (ATXS) Advances Phase 3 Trial for Hereditary Angioedema Treatment - GuruFocus
Astria Therapeutics expands phase 3 HAE trial to European Union - Investing.com India
Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):